54 results
8-K
EX-10.1
PCSA
Processa Pharmaceuticals Inc
30 Jan 24
Processa Pharmaceuticals Announces Pricing of $7.0 Million Public Offering
10:46am
Control of the U.S. Treasury Department (“OFAC”).
(mm) U.S. Real Property Holding Corporation. The Company is not and has never been a U.S. real
8-K
PCSA
Processa Pharmaceuticals Inc
21 Sep 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:29pm
Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the previous 30 consecutive business days, the bid
8-K
EX-10.1
2jfx2fla6mbd 5lax
24 Mar 22
Entry into a Material Definitive Agreement
4:30pm
8-K
EX-1.1
sxqvhnioys jif3
20 Aug 21
Entry into a Material Definitive Agreement
4:30pm
8-K
EX-10.1
yzitst
17 Jun 21
PROCESSA PHARMACEUTICALS ENTERS INTO A LICENSING AGREEMENT WITH OCUPHIRE PHARMA, INC., FOR the Development of RX-3117
11:35am
8-K
EX-10.1
6pi9bi897r4jhf4 4b
18 Feb 21
Processa Pharmaceuticals Announces $10.2 Million Strategic Financing
10:08am
8-K
EX-1.1
dwejpqyk8 tik2bh
6 Oct 20
Processa Pharmaceuticals Announces Pricing of $19.2 Million Public Offering and Uplisting to the Nasdaq Capital Market
4:05pm
424B4
z169fvma3x2j838mp
5 Oct 20
Prospectus supplement with pricing info
4:16pm